We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Liver Biomarkers Tied to Glycemic Control in Diabetes

By LabMedica International staff writers
Posted on 10 Oct 2019
As liver biomarkers serve as an effective indicator of liver injury in patients whom liver functions are somewhat above average. More...
The abnormality of these markers acts as a worrying sign to the liver function.

Since type 2 diabetes can negatively affect the liver via insulin resistance, these biomarkers maybe linked with the severity of the disease. The association between abnormal hepatic enzyme, lipid levels and glycemic control in patients with type 2 Diabetes Mellitus (T2D) has been assessed.

Clinical scientists from the Ajman University (Ajman, United Arab Emirates) determined whether a relationship exists between abnormal serum hepatic enzymes, lipid levels, and glycemic control in T2D, and conducted a cross-sectional study of 453 patients with T2D (mean age, 54.47 years) from a private healthcare center. They collected sociodemographic, clinical, and laboratory data for each patient from medical records.

The investigators found that of the total population, 80.8% had abnormal levels of one of the tested hepatic enzymes (alanine transaminase [ALT], aspartate transaminase [AST], and albumin), 6.4% had two abnormal parameters, and 2.4% had more than two abnormal parameters. On an individual level, 13.9% had abnormal ALT levels, 3.8% had abnormal AST levels, and 84.5% had abnormal albumin levels. There were no significant differences in abnormal serum hepatic enzymes between men and women.

The team used statistical modeling, and found that all three mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D (hemoglobin A1c [HbA1c] ≥7%): an albumin increase of 1 g/dL yielded a 52.7% decrease in risk for poor glycemic control, and an ALT or AST increase of 10 U/L yielded a 36% and 53% increase for HbA1c ≥7%. Furthermore, lipid profiles were also significantly associated with abnormal hepatic levels.

Odds of having abnormal ALT were significantly higher with incremental increases in body mass index, HbA1c, triglycerides, and total cholesterol levels. Odds of having abnormal AST were significantly higher with increases in HbA1c and lower with increases in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Odds of having abnormal hepatic albumin correlated to increases in body mass index, while increases in high-density lipoprotein cholesterol and triglyceride levels were associated with lower odds of having abnormal albumin.

The authors concluded that they had demonstrated that high ALT is characteristic of patients with T2D, pointing to the fact that the development of hepatic anomalies with poor glycemic control attendants could indicate unfavorable evolution of T2D. The study was available online since August 31, 2019, in the journal Obesity Medicine.

Related Links:
Ajman University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.